

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Learn About Cancer & Treatment](#)

[Tangible Materials Available for Licensing](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA

CDH6 and *CDKN2A* genes. These cells do not express the enzyme telomerase reverse transcriptase (hTERT) and consequently lack telomerase activity. This correlates with significantly reduced tumorigenicity *in vitro* and *in vivo*. These cells, however, display characteristics of alternative telomere lengthening (ALT) mechanisms (i.e., heterogeneity of telomere lengths and the presence of distinct nuclear structures called ALT-associated promyelocytic leukemia bodies). The SK-LU-1 cells do not form tumors when injected into immunocompromised mice.

Source

This cell line was established in 1969 from a 60-year-old Caucasian female with adenocarcinoma of the lung.

Inventors

Chester M. Southam, MD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

- Fogh J et al. (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. *Journal of the National Cancer Institute* 58: 209-214 (PubMed ID: [833871](#))
- Lehman TA et al. (1991) p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. *Cancer Research* 51: 4090-4096 (PubMed ID: [1855224](#))
- Brachner A et al. (2006) Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. *Cancer Research* 66: 3584-3592 (PubMed ID: [16585183](#))

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

- Express License: For internal research purposes by a for-profit entity: 1) Fill out MSK's ATCC Express License, see [here](#) for links to the online fillable ATCC Express License, as well as a PDF version. 2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see [here](#) . Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to \$10,000 must be made by credit card.
- Commercial License: Contact MSK's Tangible Materials team at TRMOTDRTM@mskcc.org .
- For non-licensing requests from academic-research institutions : Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, [646-888-2354](tel:646-888-2354) , weisgarf@mskcc.org

Stage of Development

Ready to use

Indications

[Cancer](#) > [Lung](#)

Types

[Research Tools](#) > [Cell Lines](#)

